Short Interest in PURE Bioscience (OTCMKTS:PURE) Decreases By 65.0%

PURE Bioscience (OTCMKTS:PURE) saw a large decline in short interest during the month of July. As of July 15th, there was short interest totaling 3,865 shares, a decline of 65.0% from the June 30th total of 11,031 shares. Based on an average trading volume of 68,596 shares, the short-interest ratio is currently 0.1 days. Approximately 0.0% of the company’s shares are short sold.

PURE Bioscience Trading Down 12.8%

PURE stock traded down $0.01 during midday trading on Monday, hitting $0.07. The company had a trading volume of 377 shares, compared to its average volume of 32,201. PURE Bioscience has a 52 week low of $0.04 and a 52 week high of $0.14. The stock has a market cap of $8.70 million, a price-to-earnings ratio of -2.23 and a beta of 0.22. The stock’s 50 day moving average price is $0.07 and its 200 day moving average price is $0.06.

PURE Bioscience (OTCMKTS:PURE) last issued its earnings results on Monday, June 15th. The company reported ($0.01) EPS for the quarter. The company had revenue of $0.51 million for the quarter.

About PURE Bioscience

PURE Bioscience, Inc is a San Diego, California–based company that develops and markets patented antimicrobial solutions for diverse industries. At the core of its technology portfolio is Silver Dihydrogen Citrate (SDC), an EPA-registered broad-spectrum biocide designed to neutralize bacteria, viruses, and fungi on contact. The company targets applications in food processing, water treatment, personal care, and medical device sanitation.

PURE’s product suite includes concentrate formulations and ready-to-use solutions.